Almirall

This sponsor has funded 6 studies across 5 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
4902 Finalised Evaluation of patients with chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD) who would benefit from aclidinium bromide... Yes No
6559 Finalised Aclidinium Bromide Drug Utilisation Post-Authorisation Safety Studies (DUS): Common Protocol for Aclidinium (DUS1) and Aclidinium/Formoterol... No No
6573 Finalised Real-life effectiveness evaluation of the long-acting muscarinic antagonist aclidinium bromide (Eklira®) for the management of COPD in a routine UK... Yes Yes
28457 Ongoing An Observational Post-Authorisation Safety Study of Skilarence in European Psoriasis Registers Yes No
29842 Finalised Retrospective chart review to assess the effectiveness of the Skilarence® risk minimisation activities in daily practice – a post-authorisation safety... No No
37946 Ongoing Tildrakizumab Post-Authorisation Safety Study (PASS) in European Psoriasis Registries (M-14745-40) No No

PAS by Risk Management Plan (RMP) requirement

Almirall

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.